A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease

Phase 1

Completed

• Conditions: Perianal Fistula; Crohn's Disease
• Interventions: Drug: Human TH-SC01 cell injection

• Registration Number: NCT05626023
• Lead Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of human TH-SC01 cell injection for the treatment of perianal fistulas in Crohn's Disease

Detailed Description

This study is a phase 1, single-arm, safety and tolerability study of human TH-SC01 cell injection for perianal fistulas in Crohn's Disease.

Study Timeline

• Study Start: 2022-01-30
• Study First Submitted: 2022-10-26
• Study First Submitted QC: 2022-11-15
• Study First Posted: 2022-11-23
• Primary Completion: 2023-08-30
• Study Completion: 2025-02-28
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-27
• Last Update Posted: 2025-04-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

1. Signed informed consent.
2. Subjects with Crohn's disease diagnosed at least 6 months earlier according to the Chinese Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel Diseases (Beijing, 2018).
3. Subjects with active perianal fistula and non active luminal CD defined by a CDAI ≤ 200.
4. Subjects with perianal fistula confirmed by clinical assessment and MRI.
5. Subjects aged between 18 and 70, both male and female.
6. All subjects and their partners were not planning to have a child from screening to the end of the trial and agreed to use effective non-drug contraception during the trial.
7. Subjects failed to respond to adequate treatment with any of the conventional antibiotics, immunomodulatory drugs (including steroids), anti-tumor necrosis factor-α (TNF-α) monoclonal antibodies and other biological agents.

Exclusion Criteria

1. Subjects with active infection evaluated by the investigator.
2. Subjects with Crohn's disease requiring immediate therapy.
3. Subjects with abscess or collections >2 cm.
4. Subjects with rectal and/or anal stenosis and/or active proctitis.
5. Subjects who treated with systemic steroids in the 4 weeks prior to stem cells administration.
6. Subjects with abnormal laboratory results: liver function: total bilirubin >=1.5 × ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >=2 × ULN; renal function: creatinine clearance below 60 mL/minute calculated using Cockcroft-Gault formula or by serum creatinine >=1.5 × upper limit of normal (ULN).
7. Subjects with malignant tumors or a history of malignant tumors.
8. Subjects with severe, progressive, uncontrolled hepatic, hematological, gastrointestinal (except Crohn's disease), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases.
9. Serum virology test (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody) positive.
10. Subjects allergic to gentamicin sulfate, anesthetics or contrast media.
11. Subjects allergic to MRI contrast.
12. Subjects who has received stem cells in a previous clinical study or as a therapeutic agent.
13. Subjects who has major surgery or severe trauma within 6 months prior to the screening period.
14. Subjects who has received any investigational drug within 3 months prior to the screening.
15. Subjects deemed inappropriate by the investigator to participate in this clinical trial.
16. The female participant who is pregnant, or is lactating.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Human TH-SC01 cell injection	Human TH-SC01 cell injection	Single injection of 0.6×10\^7, 1.2×10\^8, 1.8×10\^8 cells/kg

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD)	84 days	Exploration of maximum tolerated dose (MTD)
Severity and incidence of adverse events	28 days	Severity and incidence of adverse events within 28 days after adiministration
Dose-limiting toxicity (DLT)	84 days	Exploration of dose-limiting toxicity (DLT)

Secondary Outcome Measures

Name	Time	Method
Crohn's Disease Activity Index (CDAI) score	84 days	Change from baseline in the Crohn's Disease Activity Index (CDAI) score. Higher score means more severe disease and especially severe disease was defined as a value of greater than 450.
Perianal fistula healing	84 days	Change from baseline in Van Assche Score by MRI test. The score range was from 0 to 25. Higher score means more severe disease.
Perianal Disease Activity Index (PDAI)	84 days	Change from baseline in Perianal Disease Activity Index (PDAI). Total score ranges from 0 to 20. Higher score means more severe disease.
Inflammatory Bowel Disease Questionnaire（IBDQ）score	84 days	Change from baseline in IBDQ score. Total score ranges from 32 to 224. Higher score means better quality of life.
VAS score	84 days	Change from baseline in pain score (VAS score).Total score ranges from 0 to 10. Higher score means more pain.
Anal sphincter function：Wexner incontinence score	84 days	Change from baseline in anal sphincter function, Wexner incontinence score,Total score ranges from 0 to 20. Higher score means more severe disease.
Anal sphincter function： rectal pressure	84 days	Change from baseline in rectal pressure，In healthy people, the pressure ranges from 60 to 150mmHg, with the internal sphincter pressure accounts for about 80% and external sphincter pressure accounts for 20%.

Trial Locations

Locations (1)

Shanghai; 🇨🇳 Shanghai, Shanghai, China